Less Ads, More Data, More Tools Register for FREE

Pin to quick picksThg Regulatory News (THG)

Share Price Information for Thg (THG)

Share Price is delayed by 15 minutes
Get Live Data
33.36    0.36 (1.09%)
Bid:
33.16
Ask:
33.42
Spread: 0.26 (0.784%)
Market Cap: £529.37m
THG Live PriceLast checked at - London Stock Exchange

Intraday Thg Share Chart

Equity Raise Post-Transaction Report

15 Oct 2024 16:29

RNS Number : 2983I
THG PLC
15 October 2024
Β 

Β 

Β 

For immediate release

Β 

Β 

15 October 2024

THG PLC

Equity Raise Post-Transaction Report

Β 

In accordance with the Statement of Principles (November 2022) published by the Pre-Emption Group, THG PLC ("THG", the "Company"), announces the following post transaction report in connection with the Company's non-pre-emptive issue of equity securities, as announced on 11 October 2024.

Β 

Terms defined in the placing announcement issued on 10 October 2024 (the "Placing Announcement") have the same meanings in this announcement unless the context provides otherwise.

Β 

Name of Issuer

THG PLC

Transaction Details

The Company issued 194,722,333 new Ordinary Shares in total pursuant to the Fundraise (comprising 138,265,306 Placing Shares, 45,408,163 Subscription Shares and 11,048,864 Retail Offer Shares), representing approximately 14.6% of the Company's existing issued Ordinary Shares prior to the Fundraise.

Β 

Settlement and admission of the Placing Shares, the Subscription Shares and the Retail Offer Shares took place at 8.00 am on 15 October 2024.

Use of Proceeds

As set out in the Placing Announcement and the result of placing announcement issued on 11 October 2024, approximately Β£75 million of net institutional proceeds of the Fundraise will be used to provide IngenuityCo with sufficient medium-term funding (in tandem with appropriate standalone debt issuance plans) and the net proceeds raised in excess of Β£75 million will be used for general corporate purposes.

Quantum of Proceeds

The aggregate proceeds from the Fundraise amounted to approximately Β£95.4 million.

Β 

Discount

The Placing Price of 49 pence represented a discount of approximately 5.2 per cent. to the closing price on 10 October 2024.

Allocations

Soft pre-emption has been adhered to in the allocations process, where possible. Management was involved in the allocations process, which has been carried out in compliance with the MIFID II Allocation requirements.

Consultation

The Company consulted with a number of its major shareholders prior to the Fundraise, with certain of the Company's long-term shareholders indicating their intention to subscribe for, in aggregate, Β£33 million of new Ordinary Shares at the Placing Price pre-launch as set out in the Placing Announcement.

Retail Investors

The Fundraise included a Retail Offer via the PrimaryBid platform, for a total of 11,048,864 Retail Offer Shares, raising gross proceeds of approximately Β£5.4 million.

Β 

Retail investors, who participated in the Retail Offer, were able to do so at the same Placing Price as all other investors participating in the Fundraise.

Β 

The Retail Offer was made available to existing shareholders and new investors in the UK. Investors were able to participate through PrimaryBid's platform via its partner network (covering 60+ FCA registered intermediaries) and through PrimaryBid's free-to-use direct channel. Investors had the ability to participate in this transaction through ISAs and SIPPs, as well as General Investment Accounts (GIAs). This combination of participation routes meant that, to the extent practicable on the transaction timetable, eligible UK retail investors (including certificated retail shareholders) had the opportunity to participate in the Capital Raise alongside institutional investors.

Β 

Β 

Β 

Β 

For further information, please contact:

Β 

Investor Enquiries:

Greg Feehely, SVP Investor Relations

Kate Grimoldby, Director of Investor Relations and Strategic Projects

Investor.Relations@thg.com

Media enquiries:

Β 

Sodali & Co - Financial PR adviser

Victoria Palmer-Moore / Russ Lynch

+44 (0)20 7250 1446

thg@sodali.com

THG PLC

Viki Tahmasebi

Viki.tahmasebi@thg.com

Barclays (Joint Global Coordinator, Joint Bookrunner and Joint Corporate Broker):

Alastair Blackman

Dominic Harper

Callum West

+44 (0)20 7623 2323

Jefferies International Limited (Joint Global Coordinator, Joint Bookrunner and Joint Corporate Broker):

Philip Noblet

Ed Matthews

Gavriel Lambert

+44 (0)20 7029 8000

Peel Hunt LLP (Joint Bookrunner)Β George SellarΒ Sohail AkbarΒ Andrew Clark

+44 (0)20 7418 8900

Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
IOEFFAFIIELSEES
Date   Source Headline
22nd May 20267:00 amRNSNotice of AGM
21st Apr 20267:00 amRNSTrading Statement
20th Apr 20264:45 pmRNSNotice of Q1 Trading Update
8th Apr 20267:00 amRNSAnnual Report & Accounts 2025
26th Mar 20267:00 amRNSPreliminary FY 2025 results
25th Mar 20264:54 pmRNSNotice of Results
24th Feb 20267:45 amRNSPDMR/PCA Shareholding & TR-1 Notification
12th Feb 20267:00 amRNS-RMyprotein licensing partnership with Greencore
2nd Feb 20267:00 amRNSTotal Voting Rights
27th Jan 20263:49 pmRNSTR-1: Notification of major holdings
27th Jan 20263:45 pmRNSTR-1: Notification of Major Holdings
23rd Jan 20262:52 pmRNSTR-1: Notification of Major Holdings
22nd Jan 20263:00 pmRNSApplication for Listing and Total Voting Rights
16th Jan 20267:00 amRNSChange to Board Committee Membership
13th Jan 20267:00 amRNSQ4 2025 Trading Statement
12th Jan 20264:40 pmRNSNotice of Results
2nd Jan 20267:00 amRNSTotal Voting Rights
2nd Jan 20267:00 amRNSTotal Voting Rights
19th Dec 20252:20 pmRNSTR-1: Notification of Major Holdings
19th Dec 20252:20 pmRNSTR-1: Notification of Major Holdings
16th Dec 20255:50 pmRNSTR-1: Notification of Major Holdings
9th Dec 20254:35 pmRNSTR-1: Notification of Major Holdings
9th Dec 202510:55 amRNSTR-1: Notification of Major Holdings
9th Dec 20259:15 amRNSPDMR/PCA Shareholding & TR-1 Notification
5th Dec 202510:15 amRNSDirector Declaration
5th Dec 202510:05 amRNSAdmission of Convertible Loan Shares and TVR
26th Nov 20259:45 amRNSPDMR/PCA Shareholdings
17th Nov 20257:00 amRNS-RMyprotein joins forces with Mars
3rd Nov 20257:00 amRNSBlock listing Interim Review
28th Oct 202511:14 amRNSDirector Declaration
14th Oct 20257:00 amRNSQ3 2025 Trading Statement
10th Oct 20257:00 amRNSNotice of Trading Update
19th Sep 20256:00 pmRNSOcean Wilsons
11th Sep 20257:00 amRNSInterim results for half-year ended 30 June 2025
10th Sep 20254:45 pmRNSNotice of Interim Results
5th Sep 20257:00 amRNSNotification under UKLR 6.4.9R(2)
6th Aug 20257:42 amRNSDisposal, H1 trading and Nutrition update - Amend
6th Aug 20257:00 amRNSDisposal, H1 trading and Nutrition update
9th Jul 20252:24 pmRNSChanges to Directors’ Responsibilities
25th Jun 20252:38 pmRNSResult of AGM
25th Jun 20257:00 amRNSAGM Trading Statement
5th Jun 20253:56 pmRNSTR-1: Notification of Major Holdings
23rd May 20257:00 amRNSNotice of AGM
1st May 20257:00 amRNSBlock Listing Six Monthly Return
30th Apr 20257:00 amRNSAnnual Report & Accounts 2024
29th Apr 20257:00 amRNSFY 2024 results and Q1 trading statement
23rd Apr 20257:00 amRNSResponse to media speculation
16th Apr 20254:45 pmRNSTR-1: Notification of Major Holdings
4th Apr 202510:30 amRNSTR-1: Notification of Major Holdings
4th Apr 20257:00 amRNSCompletion of debt refinancing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.